299 related articles for article (PubMed ID: 23229142)
21. Synthesis, biological evaluation and modeling studies of terphenyl topoisomerase IIα inhibitors as anticancer agents.
Qiu J; Zhao B; Zhong W; Shen Y; Lin H
Eur J Med Chem; 2015 Apr; 94():427-35. PubMed ID: 25800514
[TBL] [Abstract][Full Text] [Related]
22. Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication.
Sng JH; Heaton VJ; Bell M; Maini P; Austin CA; Fisher LM
Biochim Biophys Acta; 1999 Mar; 1444(3):395-406. PubMed ID: 10095062
[TBL] [Abstract][Full Text] [Related]
23. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
Zhou Z; Guan H; Kleinerman ES
Mol Cancer Res; 2005 May; 3(5):271-5. PubMed ID: 15886298
[TBL] [Abstract][Full Text] [Related]
24. Cyclometalated platinum(II) complexes as topoisomerase IIα poisons.
Liu J; Leung CH; Chow AL; Sun RW; Yan SC; Che CM
Chem Commun (Camb); 2011 Jan; 47(2):719-21. PubMed ID: 21072335
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-β-benzyl ester derivatives as potent topoisomerase IIα inhibitors.
Han X; Zhong Y; Zhou G; Qi H; Li S; Ding Q; Liu Z; Song Y; Qiao X
Bioorg Med Chem; 2017 Jun; 25(12):3116-3126. PubMed ID: 28462840
[TBL] [Abstract][Full Text] [Related]
26. DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy.
Chikamori K; Grozav AG; Kozuki T; Grabowski D; Ganapathi R; Ganapathi MK
Curr Cancer Drug Targets; 2010 Nov; 10(7):758-71. PubMed ID: 20578986
[TBL] [Abstract][Full Text] [Related]
27. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
[TBL] [Abstract][Full Text] [Related]
28. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
29. Gene regulation and priming by topoisomerase IIα in embryonic stem cells.
Thakurela S; Garding A; Jung J; Schübeler D; Burger L; Tiwari VK
Nat Commun; 2013; 4():2478. PubMed ID: 24072229
[TBL] [Abstract][Full Text] [Related]
30. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
[TBL] [Abstract][Full Text] [Related]
31. C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.
Linka RM; Porter AC; Volkov A; Mielke C; Boege F; Christensen MO
Nucleic Acids Res; 2007; 35(11):3810-22. PubMed ID: 17526531
[TBL] [Abstract][Full Text] [Related]
32. Novel ametantrone-amsacrine related hybrids as topoisomerase IIβ poisons and cytotoxic agents.
Zagotto G; Gianoncelli A; Sissi C; Marzano C; Gandin V; Pasquale R; Capranico G; Ribaudo G; Palumbo M
Arch Pharm (Weinheim); 2014 Oct; 347(10):728-37. PubMed ID: 25042690
[TBL] [Abstract][Full Text] [Related]
33. Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
Kashyap M; Kandekar S; Baviskar AT; Das D; Preet R; Mohapatra P; Satapathy SR; Siddharth S; Guchhait SK; Kundu CN; Banerjee UC
Bioorg Med Chem Lett; 2013 Feb; 23(4):934-8. PubMed ID: 23321564
[TBL] [Abstract][Full Text] [Related]
34. Sequence determinants of nuclear localization in the alpha and beta isoforms of human topoisomerase II.
Mirski SE; Gerlach JH; Cole SP
Exp Cell Res; 1999 Sep; 251(2):329-39. PubMed ID: 10471318
[TBL] [Abstract][Full Text] [Related]
35. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
Herzog CE; Holmes KA; Tuschong LM; Ganapathi R; Zwelling LA
Cancer Res; 1998 Dec; 58(23):5298-300. PubMed ID: 9850052
[TBL] [Abstract][Full Text] [Related]
36. Alternative RNA Processing of Topoisomerase IIα in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform.
Kanagasabai R; Serdar L; Karmahapatra S; Kientz CA; Ellis J; Ritke MK; Elton TS; Yalowich JC
J Pharmacol Exp Ther; 2017 Jan; 360(1):152-163. PubMed ID: 27974648
[TBL] [Abstract][Full Text] [Related]
37. HU-331 is a catalytic inhibitor of topoisomerase IIα.
Regal KM; Mercer SL; Deweese JE
Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
[TBL] [Abstract][Full Text] [Related]
38. CS1 is a novel topoisomerase IIα inhibitor with favorable drug resistance profiles.
Shen Y; Chen W; Zhao B; Hao H; Li Z; Lu C; Shen Y
Biochem Biophys Res Commun; 2014 Oct; 453(3):302-8. PubMed ID: 25242524
[TBL] [Abstract][Full Text] [Related]
39. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.
Emmons M; Boulware D; Sullivan DM; Hazlehurst LA
Biochem Pharmacol; 2006 Jun; 72(1):11-8. PubMed ID: 16678798
[TBL] [Abstract][Full Text] [Related]
40. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
Withoff S; van der Zee AG; de Jong S; Hollema H; Smit EF; Mulder NH; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):748-53. PubMed ID: 10070864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
